English, Article edition: Health-Related Quality of Life (HR-QOL) and Regulatory Issues: An Assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) Recommendations on the Use of HR-QOL Measures in Drug Approval Giovanni Apolone; Gianfranco De Carli; Massimo Brunetti; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/118353
Physical Description
  • article
Language
  • English

Edition details

Title
  • Health-Related Quality of Life (HR-QOL) and Regulatory Issues: An Assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) Recommendations on the Use of HR-QOL Measures in Drug Approval
Author
  • Giovanni Apolone
  • Gianfranco De Carli
  • Massimo Brunetti
  • Silvio Garattini
Physical Description
  • article
Notes
  • Interest in measuring qualitative aspects of life that are most closely related to health and healthcare has increased in recent years. Methods of describing patients' subjective health status now incorporate standardised measures, and several psychometric measures are available. Despite the thousands of empirical and conceptual papers in the medical and pharmacological literature on health-related quality of life (HR-QOL), the value of such measures in the regulatory process is still being debated. We conducted an assessment to understand and document the position of the European Agency for the Evaluation of Medicinal Products (EMEA) on the use of HR-QOL measures in studies conducted for regulatory purposes. Official documents produced and circulated by the EMEA containing recommendations on trial design, conduct and analysis for sponsors and scientific experts were independently reviewed by authors to document the position of the Agency on the specific topic of HR-QOL. All documents found in the Agency website on 30 September 1999 were identified and then assessed to: 1. identify diseases or drugs for which formal HR-QOL assessment is recommended; 2. identify measures and methods recommended; and 3. evaluate the reliability of recommendations across documents. Of the 189 documents retrieved, none focused directly on health-related quality of life. A few explicit recommendations were identified for 13 specific drugs or conditions. These recommendations were mostly general and vague, and used nonstandard terminology. In addition, terminology and recommendations were not consistent across documents and, in at least one case, were in contrast with the US Food and Drug Administration (FDA) guidelines. EMEA guidelines incorporating quality-of-life outcomes are welcomed but it is obvious that more detailed guidance is required. Closer collaboration between the EMEA and the FDA is also recommended. Experts from different disciplines should be involved in the preparation of such documents to assure the necessary technical expertise and the representativeness of the various counterparts.
  • Pharmacoeconomics, Quality of life
  • RePEc:wkh:phecon:v:19:y:2001:i:2:p:187-195
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment